BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    

QT 5, Inc. Teams With World Class R&D Lab To Develop Urban Area Bio Agent Monitor For The Homeland Defense Department

10/19/2005 5:10:32 PM

WESTLAKE VILLAGE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- QT 5, Inc. (BULLETIN BOARD: QTFV) , manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it is a key participant in a recent Homeland Defense Dept. proposal to develop a robust compact system capable of autonomously monitoring outdoor urban areas for a broad range of biological agents. The proposal was submitted by MATECH Advanced Materials, a recognized global leader in the areas of optical and electronic sciences, bio-materials and high temperature ceramics. QT 5, Inc. will be providing the cassettes and membranes employed by the system.

This opportunity is a direct result of QT 5, Inc.'s recently announced acquisition of an extensive line of patented biological diagnostic devices and platforms. Company Medical Advisor Howard J. Wilner, M.D. states, "The QT 5, Inc. diagnostic platform is a cost effective solution for the rapid qualitative and quantitative analysis of a wide variety of infectious agents, including those biological threats which are of greatest concern to our Homeland Defense Dept." Dr. Wilner has served as the Clinical Chief of Medicine at Cedars-Sinai Medical Center as well as the Executive Director of the Cedars-Sinai Comprehensive Cancer Center from 1988 through 1997.

According to QT 5, Inc. CEO Timothy J. Owens, "We are quickly learning that the opportunities and applications of our diagnostic products are even more far-reaching than we anticipated. By securing the right to market these products under the manufacturer's existing US Dept. of Defense and US Dept. of Justice numbers, we have been propelled into one of the largest potential current and future user bases for these products."

About QT 5, Inc.

QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause the results of QT 5, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes no obligation and does not intend to update these forward-looking statements.

QT 5, Inc.

CONTACT: Steve Reder, President, QT 5, Inc., +1-818-338-1510,; Media, Peter Berk, ext. 205,, or J.P.Lincoln, ext. 201,, both of Crier Communications,+1-310-274-1072, for QT 5, Inc.

Read at